{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/breastfeeding-problems/prescribing-information/erythromycin-clarithromycin/","result":{"pageContext":{"chapter":{"id":"4727ad63-3ff6-54b1-867f-894d33d550d2","slug":"erythromycin-clarithromycin","fullItemName":"Erythromycin and clarithromycin","depth":2,"htmlHeader":"<!-- begin field 961d622b-016e-4c5f-9f0b-a6f601579b3e --><h2>Erythromycin and clarithromycin</h2><!-- end field 961d622b-016e-4c5f-9f0b-a6f601579b3e -->","summary":"","htmlStringContent":"<!-- begin item 440b5fb8-d742-446f-b858-a6f601579951 --><!-- begin field 1dff4a35-5ece-4c53-a25d-a6f601579b3e --><ul><li>Only small amounts of erythromycin are found in breast milk, and it is not known to be harmful when breastfeeding. Clarithromycin is excreted in breast milk, and the manufacturer advises it should only be used if the potential benefit to the mother outweighs the potential risk to the infant.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/breastfeeding-problems/references/\">BNF 72, 2016</a>]</p><!-- end field 1dff4a35-5ece-4c53-a25d-a6f601579b3e --><!-- end item 440b5fb8-d742-446f-b858-a6f601579951 -->","topic":{"id":"4d56065b-4316-58f6-aae8-5f7154ca6148","topicId":"c8e357d0-0bb7-413a-bc3b-caf10d9584ce","topicName":"Breastfeeding problems","slug":"breastfeeding-problems","lastRevised":"Last revised in May 2017","chapters":[{"id":"f183a7e4-fb16-5c51-8e82-8040a8fd2543","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"6c3771ea-501b-5f7e-8d4f-d1142d882322","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"2e3dcd26-e84a-59d0-8323-03f0685cd6a1","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"acf6ae76-da75-5e22-97ae-25b268d9bd76","slug":"changes","fullItemName":"Changes"},{"id":"2a520e88-6970-5c6c-81ab-6f85a403dbdf","slug":"update","fullItemName":"Update"}]},{"id":"e7b1ffd6-53e0-5248-9ef9-c3d9335bcaf8","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"afea2557-003c-5cab-9d6a-1843fad84de1","slug":"goals","fullItemName":"Goals"},{"id":"84c298f8-a5b4-5f98-b2ff-15a45fcb4f26","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"f21fc58c-8a25-5b15-a6bc-e737e68b787c","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"d379cce3-06f5-500f-8022-947483b96061","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"5e716806-4895-5480-a837-2377a13b6842","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"3da2e4cd-2a4d-5ed8-9747-eb0ca53b146d","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"5ea41579-133a-58f2-84ff-408513f6ec84","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"31ec7fd5-e27e-52f3-b236-31efd054a396","slug":"definition","fullItemName":"Definition"},{"id":"2a023940-e489-5105-8632-13827c70ea6a","slug":"causes-of-breast-pain","fullItemName":"Causes of breast pain"},{"id":"9c0c022a-236d-5b78-8edb-8e7db2f37e29","slug":"causes-of-nipple-pain","fullItemName":"Causes of nipple pain"},{"id":"223571de-a0b7-5f12-bec5-8a80ace52548","slug":"causes-of-low-milk-supply","fullItemName":"Causes of low milk supply"},{"id":"83d5346e-7f4a-522d-9773-4a6dd40c604e","slug":"causes-of-milk-oversupply","fullItemName":"Causes of milk oversupply"}]},{"id":"82725ef1-b602-5cb0-9269-61529b6c2b02","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"b1de0ed8-0423-5ead-aa5d-5cff64d0c321","slug":"assessment","fullItemName":"Assessment"},{"id":"472503aa-271b-514d-b4de-814e67a7a751","slug":"diagnosis-of-breast-pain","fullItemName":"Diagnosis of breast pain"},{"id":"4cc8cba0-c1f6-58b0-a13b-89abe37d504a","slug":"diagnosis-of-nipple-pain","fullItemName":"Diagnosis of nipple pain"},{"id":"f5afa158-bf6a-5287-91d4-87b5c001b13f","slug":"diagnosis-of-low-milk-supply","fullItemName":"Diagnosis of low milk supply"},{"id":"f8136aa4-95ef-5fdd-be27-e87dd0245585","slug":"diagnosis-of-milk-oversupply","fullItemName":"Diagnosis of milk oversupply"}]},{"id":"ca97794b-54f8-5bef-80ca-c5524975c2ad","fullItemName":"Management","slug":"management","subChapters":[{"id":"f9f8c0db-f1cc-552d-94f3-3bf6fc0028c5","slug":"breastfeeding-problems-management","fullItemName":"Scenario: Breastfeeding problems - management"}]},{"id":"1cfd7617-7b51-58ed-ab16-896215c43349","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"8bef9e53-ca1d-5b61-8b12-8b014e6bd3ec","slug":"paracetamol","fullItemName":"Paracetamol"},{"id":"1eaac104-bf91-5b86-afd3-c5d5437e4e93","slug":"flucloxacillin","fullItemName":"Flucloxacillin"},{"id":"4727ad63-3ff6-54b1-867f-894d33d550d2","slug":"erythromycin-clarithromycin","fullItemName":"Erythromycin and clarithromycin"},{"id":"6cd5a8b3-d7ea-577c-919e-0e1050c25ada","slug":"fluconazole","fullItemName":"Fluconazole"},{"id":"138c913a-c62a-5e10-9697-9f868ae99220","slug":"topical-fusidic-acid","fullItemName":"Topical fusidic acid"},{"id":"46d7af18-cc56-5707-8fcf-ae4b2bed882f","slug":"topical-miconazole","fullItemName":"Topical miconazole"}]},{"id":"c0e2db87-1126-5519-94ac-7719d6dc0798","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"409d7d9d-3f69-54b8-aa5c-eea89923ea9e","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"4d3d4c30-3488-5158-acfe-2d12bdb10359","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"49e75f6f-5655-58b1-8933-8fa4c3819b8a","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"d5b6c020-e109-5b11-aefd-70df672efa79","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"87720b05-a3b7-5a75-a206-9bfc4d167e76","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"cb469aba-1f15-5f6e-bfb6-fa073612150f","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"416d347c-3b3f-530d-8323-4bb4de52b3fe","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"1cfd7617-7b51-58ed-ab16-896215c43349","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"e2713f58-b623-57ee-a934-a097b68988d6","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field e6562967-c599-4d75-8ab2-a6f6015b1bf6 --><h3>Contraindications and cautions</h3><!-- end field e6562967-c599-4d75-8ab2-a6f6015b1bf6 -->","summary":"","htmlStringContent":"<!-- begin item a55583e3-67f5-42f9-b03d-a6f6015b1b11 --><!-- begin field 8d30cb00-9a53-43f0-9ee6-a6f6015b1bf6 --><h4>Contraindications</h4><ul><li><strong>Do not prescribe:</strong><ul><li><strong>Erythromycin</strong> to people with acute porphyria.</li><li><strong>Clarithromycin</strong> to people with hypokalaemia and people with a history of QT prolongation or ventricular cardiac arrhythmia, including Torsades de pointes.</li><li><strong>Erythromycin or clarithromycin</strong> to people with severe hepatic impairment.</li></ul></li></ul><h4>Cautions</h4><ul><li><strong>Prescribe erythromycin and clarithromycin with caution to people with:</strong><ul><li>Mild to moderate hepatic impairment.</li><li>Chronic kidney disease (CKD) stages 4 and 5 — for erythromycin, use a maximum dose of 1.5 g daily in severe renal impairment, due to the risk of ototoxicity; for clarithromycin, use half the normal dose if the estimated glomerular filtration rate (eGFR) is less than 30 mL/min/1.73 m<sup>2</sup> for a maximum duration of 14 days, and avoid clarithromycin modified-release preparations.</li><li>Myasthenia gravis — symptoms may be aggravated.</li></ul></li><li><strong>Prescribe erythromycin with caution to people with</strong> a condition that predisposes them to QT interval prolongation (for example hypokalaemia).</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/breastfeeding-problems/references/\">ABPI, 2016b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/breastfeeding-problems/references/\">ABPI, 2016c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/breastfeeding-problems/references/\">BNF 72, 2016</a>]</p><!-- end field 8d30cb00-9a53-43f0-9ee6-a6f6015b1bf6 --><!-- end item a55583e3-67f5-42f9-b03d-a6f6015b1b11 -->","subChapters":[]},{"id":"4f03f044-8772-576f-bb05-208e8cf8f1f4","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 8dd4cb7a-8753-49f4-919b-a6f6015b2c49 --><h3>Adverse effects</h3><!-- end field 8dd4cb7a-8753-49f4-919b-a6f6015b2c49 -->","summary":"","htmlStringContent":"<!-- begin item 8d9a43db-0346-4f61-861f-a6f6015b2b0b --><!-- begin field 533990dd-a905-4b9f-9a0c-a6f6015b2c49 --><p><strong>Adverse effects of macrolides include:</strong></p><ul><li><strong>Nausea, vomiting, abdominal discomfort, and diarrhoea</strong> — most common, but symptoms are mild and less frequent with clarithromycin than with erythromycin.<ul><li>Consider pseudomembranous colitis if a person develops severe diarrhoea during or after treatment with erythromycin or clarithromycin. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/diarrhoea-antibiotic-associated/\">Diarrhoea - antibiotic associated</a> for more information.</li></ul></li><li><strong>Anaphylaxis</strong> (rare). See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/angio-oedema-anaphylaxis/\">Angio-oedema and anaphylaxis</a> for more information.</li><li><strong>Hepatotoxicity (including cholestatic jaundice) and rash</strong> (rare).</li><li><strong>Reversible hearing loss (sometimes with tinnitus)</strong> — can occur after large doses of erythromycin and clarithromycin.</li><li><strong>Other adverse effects reported rarely or very rarely include</strong> pancreatitis, QT interval prolongation, arrhythmias, Stevens-Johnson syndrome, and toxic epidermal necrolysis.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/breastfeeding-problems/references/\">ABPI, 2015a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/breastfeeding-problems/references/\">ABPI, 2016b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/breastfeeding-problems/references/\">BNF 72, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/breastfeeding-problems/references/\">Micromedex, 2016</a>]   </p><!-- end field 533990dd-a905-4b9f-9a0c-a6f6015b2c49 --><!-- end item 8d9a43db-0346-4f61-861f-a6f6015b2b0b -->","subChapters":[]},{"id":"95f8d085-5b79-58e7-b0f2-5a4eae8cb962","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 56543742-d610-4e93-9a75-a6f6015b3d68 --><h3>Drug interactions</h3><!-- end field 56543742-d610-4e93-9a75-a6f6015b3d68 -->","summary":"","htmlStringContent":"<!-- begin item a421359d-2b7a-43ec-a1cc-a6f6015b3c7b --><!-- begin field 1f163d0b-742d-4c89-8bf3-a6f6015b3d68 --><ul><li><strong>Possible drug interactions with erythromycin and clarithromycin include:</strong><ul><li><strong>Carbamazepine </strong>— macrolides can raise plasma carbamazepine levels.<ul><li>For erythromycin — avoid concurrent use with carbamazepine unless carbamazepine levels can be closely monitored and suitable dose adjustments made. Symptoms of carbamazepine toxicity (for example nausea, vomiting, dizziness, ataxia, and confusion) commonly begin within 1–3 days of starting erythromycin and usually resolve within 5 days of stopping erythromycin.</li><li>For clarithromycin — reduce carbamazepine dose by 30–50%, and monitor plasma levels within 3–5 days of concurrent treatment with carbamazepine.</li></ul></li><li><strong>Drugs that prolong the QT interval (such as antiarrhythmics, antipsychotics, and tricyclic antidepressants) </strong>— all macrolides can prolong the QT interval, and concomitant use of drugs that prolong the QT interval is not recommended.<ul><li>Seek advice from a microbiologist regarding a suitable alternative antibiotic.</li></ul></li><li><strong>Drugs that cause hypokalaemia (such as diuretics, corticosteroids, short-acting beta<sub>2</sub>-agonists) </strong>— hypokalaemia is a risk factor for QT interval prolongation.<ul><li>Seek advice from a microbiologist regarding a suitable alternative antibiotic.</li></ul></li><li><strong>Statins </strong>— there is an increased risk of myopathy (due to cytochrome P450 enzyme CYP3A4 inhibition) if clarithromycin or erythromycin is taken with atorvastatin or simvastatin.<ul><li>For simvastatin — do not prescribe clarithromycin or erythromycin to a person taking simvastatin, as simvastatin is extensively metabolized by CYP3A4. If treatment with clarithromycin or erythromycin cannot be avoided, stop treatment with simvastatin during the course of the treatment.</li><li>For atorvastatin — avoid concurrent use with clarithromycin or erythromycin, as atorvastatin is moderately metabolized by CYP3A4. If concurrent use cannot be avoided, prescribe the lowest dose of atorvastatin (10 mg), and advise the person to report any muscle pain, tenderness, or weakness.</li><li>Other statins — clinically significant drug interactions resulting from cytochrome P450-mediated metabolism are not expected for rosuvastatin and pravastatin as they are not metabolized to a clinically significant extent by the cytochrome P450 system. Fluvastatin is not dependent on CYP3A metabolism; therefore, interaction with clarithromycin is unlikely. Nevertheless, advise the person to report any muscle pain, tenderness, or weakness.</li></ul></li><li><strong>Theophylline </strong>— erythromycin increases plasma concentrations of theophylline, and theophylline may also reduce absorption of oral erythromycin.<ul><li>Check theophylline levels 48 hours after starting erythromycin, and adjust the dose of theophylline accordingly.</li><li>This interaction is less likely with clarithromycin, unless theophylline levels are at the higher end of the therapeutic range.</li></ul></li><li><strong>Warfarin </strong>— occasionally and unpredictably, the anticoagulant effects of warfarin may be markedly increased by macrolides.<ul><li>Monitor the international normalized ratio (INR), and adjust the warfarin dose accordingly.</li></ul></li><li><strong>Calcium channel blockers (CCBs) </strong>— due to an increased risk of hypotension, caution is advised with the concurrent use of macrolides and CCBs metabolised by CYP3A4 (such as verapamil, amlodipine, and diltiazem).</li><li><strong>Antidiabetic drugs and insulin</strong> — the concurrent use of clarithromycin and antidiabetic drugs (such as sulphonylurias and/or insulin) can result in significant hypoglycaemia.<ul><li>Monitor blood glucose levels more regularly and adjust the antidiabetic drug (and/or insulin) dose accordingly.</li></ul></li></ul></li><li><strong>Contraceptives </strong>— additional contraceptive precautions are <em>not</em> required during or after a course of clarithromycin or erythromycin.<ul><li>However, advise women on the importance of correct contraceptive practice if they experience vomiting or diarrhoea. For further information, see the section on vomiting or diarrhoea in the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/contraception-combined-hormonal-methods/\">Contraception - combined hormonal methods</a> and <a class=\"topic-reference external-reference\" href=\"/topics/contraception-progestogen-only-methods/\">Contraception - progestogen-only methods</a>.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/breastfeeding-problems/references/\">ABPI, 2015a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/breastfeeding-problems/references/\">ABPI, 2016b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/breastfeeding-problems/references/\">BNF 72, 2016</a>]</p><!-- end field 1f163d0b-742d-4c89-8bf3-a6f6015b3d68 --><!-- end item a421359d-2b7a-43ec-a1cc-a6f6015b3c7b -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}